CN1798553A - 冠状病毒灭活剂 - Google Patents
冠状病毒灭活剂 Download PDFInfo
- Publication number
- CN1798553A CN1798553A CNA200480015086XA CN200480015086A CN1798553A CN 1798553 A CN1798553 A CN 1798553A CN A200480015086X A CNA200480015086X A CN A200480015086XA CN 200480015086 A CN200480015086 A CN 200480015086A CN 1798553 A CN1798553 A CN 1798553A
- Authority
- CN
- China
- Prior art keywords
- myramistin
- coronavirus
- inactivating agent
- stage
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种miramistine(别名肉豆蔻酰胺-丙基-二甲基-苄基-氯化铵)形式的新的冠状病毒灭活剂,其以前已知作为表现抗真菌和抗微生物作用和针对HIV、流感和疱疹病毒感染有效的防腐剂。所述发明扩展了用于所述应用的活性剂的范围,并且使得治疗和预防由所述冠状病毒引起的呼吸道疾病(包括SARS)和胃肠炎成为可能。
Description
本发明涉及医学和药学工业,并可以用于治疗和预防药物的发现、生产和应用。
脂质溶剂(liposolvent)、洗涤剂和防腐剂已知是用于灭活冠状病毒的药物(L.Ya.Zakstel’skaya,A.V.Scheboldov//Human and animalcoronaviruses;Medicine,Moscow,1977,vol.2,p.221;General andparticular virology,V.M.Jdanov and S.Ya.Gaidamovich编辑,Medicine,Moscow,1982,vol.2,p.316-339;A.I.Korotyaev,S.A.Babichev//Medicinal microbiology,virology and immunology,Saint-Petersburg:《Special literature》,1998,p.273)。
我们提出了肉豆蔻酰氨基丙基二甲基苄基氯化铵(myramistin,发明人证书1832496)用于灭活冠状病毒的应用。以前这一化合物已知作为用于传统性病如梅毒、滴虫病、淋病的预防药和作为用于化脓炎症性角膜疾病(pyoinflammatory comea disease)的防腐剂(R.F.Patent2164135)。
本发明要求保护的技术方案增加了用于预防和治疗冠状病毒引起的疾病的药物的数目。
下面所给出的实施例证明了本发明的化合物的灭活效果(其中“Myramistin”用作化合物的名称以便于叙述的简单化)。
实施例1:
根据下述方案测定了对于人胚胎肾细胞培养物(体外),Myramistin对冠状病毒测试培养物(人冠状病毒OC43)的最小抑制浓度(MIC):
第1阶段 | 测试病毒+Myramistin(以相应的浓度) |
第2阶段 | 温育(2小时) |
第3阶段 | 将中和剂(例如25%胎牛血清)加入反应混合物中并温育10-20分钟 |
第4阶段 | 感染敏感细胞培养物(例如人胚胎肾细胞培养物) |
第5阶段 | 培养(5-8天) |
第6阶段 | 记录基于血细胞吸附现象和细胞吞噬活性(cytophaticactivity)-共质体形成(symplastoformation)的结果 |
对四种化合物制剂进行了三个系列的实验。基于得到的结果计算Myramistin对冠状病毒的最小抑制浓度。实验数据在下表1中给出。
表1.Myramistin和其它防腐剂对人冠状病毒OC43的体外MIC
防腐剂 | MIC(%) |
Myramistin | 0.01±0.005 |
Decamethoxin | 0.1±0.05 |
洗必泰 | 0.05±0.005 |
Etonium | 0.5±0.2 |
Dioxydine | R |
Rockal | 0.1±0.05 |
壬苯聚醇-9 | 0.2±0.09 |
吐温-20(Twin-20) | 2.0±0.8 |
注:R-冠状病毒对高于2.5%的防腐剂浓度具有耐药性。
从获得的结果(表1)可见,就冠状病毒灭活而言,与所有已知和目前使用的防腐剂相比,myramistin更有效。
实施例2:
根据下述方案进行对于幼鼠,myramistin对人冠状病毒OC43的体内MIC的测定
第1阶段 | 测试病毒+Myramistin(以相应的浓度) |
第2阶段 | 温育(30分钟) |
第3阶段 | 感染幼鼠脑或腹腔 |
第4阶段 | 记录感染后2-3天的结果(动物被膜(coverlet)充血、震颤、肌肉强直、无吸吮、死亡) |
对不同浓度的四种化合物制剂(每种制剂6只小鼠)进行三个系列的实验。以1gLD50评价病毒对幼鼠的感染进展。平均实验数在表2中给出。
表2.Myramistin对人冠状病毒OC43的感染活性的影响结果(MIC浓
度)(体内,幼鼠)
系列号 | 病毒的感染活性(lgLD50) | ||||
治疗前 | 用相应剂量治疗后(%) | ||||
0.0001 | 0.001 | 0.005 | 0.01 | ||
1 | 6.4 | 3.6 | 1.0 | 0 | 0 |
2 | 6.0 | 3.2 | 1.0 | 0 | 0 |
3 | 6.3 | 3.0 | 1.2 | 0 | 0 |
得到的结果清楚地表明,0.0001%浓度的myramistin的存在几乎使病毒的活性降低一半,而且0.005%和更高的浓度完全中和了病毒的活性。
实施例3:
基于用鸡红细胞的血凝反应(HGR)评价myramistin对冠状病毒OC43的血凝活性的影响
将浓度0.000001至0.001%的Myramistin溶液加入含有血凝滴度不小于1∶512的冠状病毒OC43的培养肉汤中。温育30分钟后,加入25%的胎牛血清以中和myramistin,然后10-20分钟后进行鸡血细胞的HGR。对不同浓度(每种浓度3例)的四种myramistin制剂进行四个系列的实验。平均实验数在表3中给出。
表3.Myramistin对冠状病毒OC43的血凝活性影响的实验结果
系列号 | 以滴度表示的血凝活性 | ||||
治疗前 | 用相应剂量治疗后(%) | ||||
0.000001 | 0.00001 | 0.0001 | 0.001 | ||
1 | 512 | 8 | 4 | 0 | 0 |
2 | 2048 | 16 | 8 | 0 | 0 |
3 | 1024 | 8 | 4 | 0 | 0 |
4 | 2560 | 16 | 8 | 0 | 0 |
从上述的实验结果可见,myramistin以比对冠状病毒的感染活性(0.0001%)更低的浓度(0.000001%)实现对冠状病毒血凝素(其使得冠状病毒吸附在敏感细胞上)的影响。
获得的实验数据清楚地证明所提出的技术方案使得可以将肉豆蔻酰氨基丙基二甲基苄基氯化铵(《myramistin》)用于灭活冠状病毒,并可用于开发治愈由冠状病毒引起的疾病的新预防药和治疗药。
Claims (1)
1.肉豆蔻酰氨基丙基二甲基苄基氯化铵(《myramistin》)用于灭活冠状病毒的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2003116391/15A RU2234313C1 (ru) | 2003-06-04 | 2003-06-04 | Средство инактивации коронавирусов |
RU2003116391 | 2003-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1798553A true CN1798553A (zh) | 2006-07-05 |
CN100350904C CN100350904C (zh) | 2007-11-28 |
Family
ID=33414532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200480015086XA Expired - Fee Related CN100350904C (zh) | 2003-06-04 | 2004-06-03 | 冠状病毒灭活剂 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1634590A4 (zh) |
KR (1) | KR20060054190A (zh) |
CN (1) | CN100350904C (zh) |
RU (1) | RU2234313C1 (zh) |
WO (1) | WO2004108125A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869354A (zh) * | 2010-02-19 | 2013-01-09 | 梅根医药股份有限公司 | 包含肉豆蔻酰氨基丙基二甲基苄基氯化铵的药物制剂 |
CN116390908A (zh) * | 2020-03-05 | 2023-07-04 | 生态合成股份有限公司 | 抗病毒治疗 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008039254A1 (de) * | 2008-08-20 | 2010-02-25 | Megainpharm Gmbh | Arzneimittel |
WO2014175757A1 (ru) | 2013-04-22 | 2014-10-30 | Общество с ограниченной ответственностью "Нанобиотех" | Антисептический ветеринарный препарат и способы его использования |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2459062A (en) * | 1944-02-08 | 1949-01-11 | American Cyanamid Co | Quaternary ammonium compounds |
SU1796185A1 (ru) * | 1990-06-23 | 1993-02-23 | Adolina P Rudko | Фунгицид 2 |
US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
WO1993000892A1 (en) * | 1991-07-10 | 1993-01-21 | Jury Semenovich Krivoshein | Pharmaceutical preparation |
-
2003
- 2003-06-04 RU RU2003116391/15A patent/RU2234313C1/ru not_active IP Right Cessation
-
2004
- 2004-06-03 KR KR1020057023103A patent/KR20060054190A/ko not_active Application Discontinuation
- 2004-06-03 EP EP04748924A patent/EP1634590A4/en not_active Withdrawn
- 2004-06-03 WO PCT/RU2004/000215 patent/WO2004108125A1/ru active Application Filing
- 2004-06-03 CN CNB200480015086XA patent/CN100350904C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869354A (zh) * | 2010-02-19 | 2013-01-09 | 梅根医药股份有限公司 | 包含肉豆蔻酰氨基丙基二甲基苄基氯化铵的药物制剂 |
CN102869354B (zh) * | 2010-02-19 | 2015-12-16 | 梅根医药股份有限公司 | 包含肉豆蔻酰氨基丙基二甲基苄基氯化铵的药物制剂 |
CN116390908A (zh) * | 2020-03-05 | 2023-07-04 | 生态合成股份有限公司 | 抗病毒治疗 |
Also Published As
Publication number | Publication date |
---|---|
CN100350904C (zh) | 2007-11-28 |
WO2004108125A1 (fr) | 2004-12-16 |
EP1634590A1 (de) | 2006-03-15 |
KR20060054190A (ko) | 2006-05-22 |
EP1634590A4 (en) | 2009-04-08 |
RU2234313C1 (ru) | 2004-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20140050608A (ko) | 유해 미생물 저해 방법 및 그를 위한 장벽-형성 조성물 | |
WO2002015844A2 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
CN1961679A (zh) | 一种复方抗病毒喷雾剂及其制备方法 | |
EP3976093A1 (en) | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same | |
RU2728939C1 (ru) | Применение даларгина для производства средств лечения коронавирусной инфекции covid-19 | |
CN1264513C (zh) | 杀病毒组合物 | |
CN100350904C (zh) | 冠状病毒灭活剂 | |
EP2529737A1 (en) | Antibacterial combination therapy | |
KR20240016954A (ko) | 분별된 꿀을 사용한 병태 치료용 조성물 및 방법 | |
RU2398596C2 (ru) | Способы профилактики и лечения заболеваний, вызванных вирусом гриппа птиц a/h5n1, с использованием индуктора интерферона и ингибитора нейраминидазы | |
WO2021130483A1 (en) | Compositions | |
WO2006099376A1 (en) | Dragon's blood anti-viral materials and methods | |
CN112843073A (zh) | 瑞德西韦(Remdesivir)在制备抗牛副流感病毒3型药物中的应用 | |
RU2753609C1 (ru) | Противовирусное гуминовое средство | |
RU2502512C2 (ru) | Способ лечения гриппа птиц | |
RU2790837C2 (ru) | Спрей для лечения инфицированных и неинфицированных ран при сахарном диабете i типа | |
CN1548152A (zh) | 溶菌酶对严重急性呼吸道综合症的治疗和预防作用 | |
Mohammadalizadehchafjiri et al. | Importance of using Chlorhexidine mouthwash prior to dental treatment: A literature review | |
RU2304969C2 (ru) | Способ коррекции антиинфекционной резистентности организма при гнойно-воспалительных процессах кандида-бактериальной этиологии на фоне экспериментальной ожоговой травмы | |
Ghosh et al. | Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry? | |
RU2458138C2 (ru) | Способ моделирования предупреждения формирования госпитальных штаммов | |
CN113318115A (zh) | 美他环素在制备防治牛副流感病毒3型病毒感染药物中的应用 | |
CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
WO2022226614A1 (pt) | Formulação para solução nasal com ação inibidora do vírus sars-cov-2 e das patologias relacionadas | |
WO2022226613A1 (pt) | Formulação para enxaguante bucal com ação inibidora do vírus sars-cov-2 e redutora das patologias relacionadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071128 Termination date: 20100603 |